AstraZeneca Launches ZEGFROVY In The U.S., Expanding Targeted Treatment Options For EGFR Exon 20 Insertion-Mutated Lung Cancer
Only approved oral, single agent, targeted therapy for these patients following platinum-based chemotherapyLaunch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of EGFR-mutated
AstraZeneca just released a new cancer medicine in America. This shows the company is growing its toolbox to help sick patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.